Tags

Type your tag names separated by a space and hit enter

Treatment of rheumatoid arthritis with roxithromycin: a randomized trial.
Postgrad Med. 2011 Sep; 123(5):220-7.PM

Abstract

BACKGROUND

High levels of antibodies to oral anaerobic bacteria have been found in the serum and synovial fluid of patients with rheumatoid arthritis (RA). Macrolide antibiotics are active against oral anaerobic bacteria. The aim of this trial was to evaluate the efficacy of roxithromycin in patients with RA who had not responded to disease-modifying antirheumatic drugs.

METHODS

This was a 6-month, randomized, double-blind, placebo-controlled trial. We treated 100 patients with active RA with either once-daily oral roxithromycin 300 mg or daily oral placebo for 6 months. The primary efficacy variable was the percentage of patients who had a 20% improvement according to the American College of Rheumatology (ACR) criteria (an ACR20 response) at 6 months. Secondary outcome measures were 50% improvement and 70% improvement according to ACR criteria (an ACR50 response and an ACR70 response, respectively).

RESULTS

A significantly greater percentage of patients treated with roxithromycin 300 mg met the ACR 20% improvement criteria (ie, achieved an ACR20 response) at 6 months compared with patients who received placebo (60% vs 34%; P = 0.009). Greater percentages of patients treated with roxithromycin 300 mg also achieved ACR50 responses (38% vs 12%; P = 0.003) and ACR70 responses (18% vs 2%; P = 0.008) compared with patients who received placebo. Roxithromycin was well tolerated, with an overall safety profile similar to that of placebo.

CONCLUSION

In patients with active RA, treatment with roxithromycin significantly improved the signs and symptoms of RA.

Authors+Show Affiliations

Nazilli State Hospital, Division of Rheumatology, Nazilli, Turkey. mogrendik@gmail.comNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

21904105

Citation

Ogrendik, Mesut, and Nihan Karagoz. "Treatment of Rheumatoid Arthritis With Roxithromycin: a Randomized Trial." Postgraduate Medicine, vol. 123, no. 5, 2011, pp. 220-7.
Ogrendik M, Karagoz N. Treatment of rheumatoid arthritis with roxithromycin: a randomized trial. Postgrad Med. 2011;123(5):220-7.
Ogrendik, M., & Karagoz, N. (2011). Treatment of rheumatoid arthritis with roxithromycin: a randomized trial. Postgraduate Medicine, 123(5), 220-7. https://doi.org/10.3810/pgm.2011.09.2478
Ogrendik M, Karagoz N. Treatment of Rheumatoid Arthritis With Roxithromycin: a Randomized Trial. Postgrad Med. 2011;123(5):220-7. PubMed PMID: 21904105.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of rheumatoid arthritis with roxithromycin: a randomized trial. AU - Ogrendik,Mesut, AU - Karagoz,Nihan, PY - 2011/9/10/entrez PY - 2011/9/10/pubmed PY - 2011/11/9/medline SP - 220 EP - 7 JF - Postgraduate medicine JO - Postgrad Med VL - 123 IS - 5 N2 - BACKGROUND: High levels of antibodies to oral anaerobic bacteria have been found in the serum and synovial fluid of patients with rheumatoid arthritis (RA). Macrolide antibiotics are active against oral anaerobic bacteria. The aim of this trial was to evaluate the efficacy of roxithromycin in patients with RA who had not responded to disease-modifying antirheumatic drugs. METHODS: This was a 6-month, randomized, double-blind, placebo-controlled trial. We treated 100 patients with active RA with either once-daily oral roxithromycin 300 mg or daily oral placebo for 6 months. The primary efficacy variable was the percentage of patients who had a 20% improvement according to the American College of Rheumatology (ACR) criteria (an ACR20 response) at 6 months. Secondary outcome measures were 50% improvement and 70% improvement according to ACR criteria (an ACR50 response and an ACR70 response, respectively). RESULTS: A significantly greater percentage of patients treated with roxithromycin 300 mg met the ACR 20% improvement criteria (ie, achieved an ACR20 response) at 6 months compared with patients who received placebo (60% vs 34%; P = 0.009). Greater percentages of patients treated with roxithromycin 300 mg also achieved ACR50 responses (38% vs 12%; P = 0.003) and ACR70 responses (18% vs 2%; P = 0.008) compared with patients who received placebo. Roxithromycin was well tolerated, with an overall safety profile similar to that of placebo. CONCLUSION: In patients with active RA, treatment with roxithromycin significantly improved the signs and symptoms of RA. SN - 1941-9260 UR - https://www.unboundmedicine.com/medline/citation/21904105/Treatment_of_rheumatoid_arthritis_with_roxithromycin:_a_randomized_trial_ L2 - https://www.tandfonline.com/doi/full/10.3810/pgm.2011.09.2478 DB - PRIME DP - Unbound Medicine ER -